Vir Biotechnology (VIR) Payables (2018 - 2026)

Vir Biotechnology (VIR) has 9 years of Payables data on file, last reported at $5.4 million in Q1 2026.

• For the quarter ending Q1 2026, Payables rose 46.17% year-over-year to $5.4 million; the trailing twelve-month figure through Mar 2026 stood at $5.4 million (up 46.17% YoY), and the FY2025 full-year result was $9.8 million, up 92.93% from the prior year.
• Payables eased to $5.4 million in Q1 2026, from $9.8 million in the prior quarter.
• In the past five years, Payables ranged from a high of $12.4 million in Q2 2023 to a low of $2.7 million in Q3 2022.
• A 5-year average of $7.5 million and a median of $6.8 million in 2025 frame the typical range for Payables.
• Across the five-year window, Payables soared 196.0% in 2022 and tumbled 64.5% in 2024, its largest moves.
• Tracing VIR's Payables over 5 years: stood at $6.4 million in 2022, then decreased by 1.37% to $6.3 million in 2023, then fell by 19.78% to $5.1 million in 2024, then surged by 92.93% to $9.8 million in 2025, then slumped by 44.46% to $5.4 million in 2026.
• Business Quant data shows VIR's Payables at $5.4 million in Q1 2026, $9.8 million in Q4 2025, and $6.8 million in Q3 2025.